|
| I型胶原吡啶交联终肽(ICTP)在骨肿瘤诊断中的临床研究 |
| Clinical study of pyridinolne cross linked carboxyterminal telopeptide of type I collagen in the diagnosis of bone tumor |
| |
| DOI：10.3969/j.issn.1006-7108.2013.10.009 |
| 中文关键词: 良性骨肿瘤 原发性恶性骨肿瘤 继发性恶性骨肿瘤 骨转移性肿瘤 I型胶原吡啶交联终肽 |
| 英文关键词:Benign bone tumor Primary malignant bone tumor Secondary malignant bone tumor Metastatic bone tumor Pyridinoline cross linked carboxyterminal telopeptide of type I collagen (ICTP) |
| 基金项目: |
|
| 摘要点击次数: 1288 |
| 全文下载次数: 1181 |
| 中文摘要: |
| 目的 检测良性骨肿瘤、恶性骨肿瘤患者及正常对照组血清中的I型胶原吡啶交联终肽(ICTP)活性，以评价ICTP在良恶性骨肿瘤诊断和鉴别诊断中的价值。方法 选取2005~2010年本院骨肿瘤科收治的78例恶性骨肿瘤患者，设为A组，其中49例为原发性恶性骨肿瘤、10例为继发性恶性骨肿瘤、19例为骨转移性肿瘤患者,另选43例良性骨肿瘤患者为B组，同时，设52例同龄正常人为C组，均采用酶免疫测定(EIA)方法测定他们血清中的ICTP活性。结果 B组患者血清ICTP活性为(6.75±3.34) μg/L，C组血清ICTP活性为(4.68±2.91) μg/L,A组患者血清ICTP活性为(14.84±8.49)μg/L，其中，原发性恶性骨肿瘤患者、继发性恶性骨肿瘤、骨转移性肿瘤患者的血清ICTP活性分别为(17.47±10.86)μg/L、(8.02±6.19) μg/L、(8.14±5.45) μg/L. A组中三类患者的血清ICTP活性与B组，C组相比差异均有统计学差异(P<0.05)，B组患者与C组相比差异无统计学差异(P>0.05)。而A组中原发性恶性骨肿瘤与继发性恶性骨肿瘤、骨转移性肿瘤组之间的差异也有统计学意义 (P<0.05)。结论 血清ICTP是反映骨肿瘤骨代谢的一个灵敏而简便的检测指标,并对良恶性骨肿瘤的诊断及鉴别诊断具有重要的临床意义。 |
| 英文摘要: |
| Objective By detecting the serum level of pyridinoline cross linked carboxyterminal telopeptide of type I collagen (ICTP) in patients with benign and malignant bone tumors and healthy controls, to investigate the clinical value of ICTP in the diagnosis and differential diagnosis in benign and malignant bone tumor. Methods Seventy-eight patients with malignant bone tumor, who were hospitalized in the Department of Bone Tumor in our hospital from 2005 to 2010, were selected as Group A. Among these 78 patients, 49 paitents had primary malignant bone tumor, 10 patients had secondary malignant bone tumor, 19 patients had metastatic bone tumor. Meanwhile, 43 patients who had benign bone tumor were selected as Group B. Fifty-two healthy controls were selected as Group C. Serum ICTP was determined using enzyme immunoassay (EIA). Results The serum level of ICTP in Group A, Group B, and Group C was 14.84±8.49 μg/L, 6.75±3.34 μg/L, and 4.68±2.91 μg/L, respectively. In Group A, the serum level of ICTP of patients with primary malignant bone tumor, secondary malignant bone tumor, and metastatic bone tumor was 17.47±10.86 μg/L, 8.02±6.19 μg/L, and 8.14±5.45 μg/L, respectively. The serum level of ICTP in Group A was significantly higher than that in Group B or C (P<0.05), while no significant difference of serum ICTP between Group B and Group C was observed (P<0.05). The serum level of ICTP of patients with primary malignant bone tumor patients was significantly higher than that of patients with secondary malignant bone tumor or metastatic bone tumor (P<0.05). Conclusion Serum ICTP is a sensitive and convenient biochemical index reflecting the bone metabolism of bone tumor, and it has important clinical significance in the diagnosis and differentital diagnosis of benign and malignant bone tumor. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|